@article{77246e5508b047cd975bff277f8db8ed,
title = "Letter to the Editor re Shen et al",
author = "{Cohen Rassier}, {Sarah L.} and Louie, {Michelle Y.} and Hopkins, {Matthew R.} and Stewart, {Elizabeth A.} and Laughlin-Tommaso, {Shannon K.}",
note = "Funding Information: Financial disclosures/conflicts of interest: E.A.S. has the following disclosures: personal fees all related to uterine fibroids from Bayer, AbbVie, ObsEva, Myovant, UpToDate, Massachusetts Medical Society, Med Learning Group, Medscape, PeerView, and PER outside the submitted work and an issued patent “Methods and Compounds for Treatment of Abnormal Uterine Bleeding” 6,440,445, which has no commercial activity. She also has funding from the National Institutes of Health related to adenomyosis (1R01HD105714). M.Y.L. has the following disclosures: consultant for Hologic Inc and Applied Medical. The remaining authors have nothing to disclose.",
year = "2022",
month = aug,
day = "1",
doi = "10.1097/GME.0000000000002043",
language = "English (US)",
volume = "29",
pages = "999",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "8",
}